Business UpdateJun 18, 2026, 07:01 AM
Veraxa Biotech Validates BiTAC-ADC Platform with New In Vitro Data
AI Summary
Veraxa Biotech announced new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform, designed to enable more precise and targeted cancer therapies. The data showed BiTAC-ADCs could discriminate between breast cancer and healthy cells and efficiently kill 3D tumor cell spheroids. The company plans to discuss partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms at the upcoming BIO International Convention, aiming to address off-tumor toxicity challenges in current ADC technologies.
Key Highlights
- Veraxa Biotech generated new in vitro proof-of-concept data for its BiTAC-ADC technology platform.
- BiTAC-ADCs demonstrated discrimination between breast cancer and healthy cells in studies.
- The technology showed efficient, dose-dependent killing of 3D tumor cell spheroids.
- BiTAC-ADC platform aims to enable more precise and targeted cancer therapies by reducing off-tumor toxicity.
- Veraxa Biotech will attend the BIO International Convention (June 22-25, 2026) to discuss partnering opportunities.
- The company now has two viable and differentiated product platform technologies: BiTAC-ADC and BiTAC-TCE.
Price Impact
More from VRXA